AbbVie (NYSE:ABBV) Price Target Cut to $230.00 by Analysts at Citigroup

AbbVie (NYSE:ABBV) had its target price reduced by Citigroup from $235.00 to $230.00 in a report released on Tuesday morning,Benzinga reports. They currently have a neutral rating on the stock.

Other research analysts also recently issued reports about the stock. UBS Group restated a “neutral” rating on shares of AbbVie in a research report on Tuesday, January 13th. BMO Capital Markets reissued an “outperform” rating and set a $258.00 price target on shares of AbbVie in a report on Thursday, January 15th. Erste Group Bank downgraded AbbVie from a “buy” rating to a “hold” rating in a research report on Tuesday, October 14th. Hsbc Global Res upgraded AbbVie from a “hold” rating to a “strong-buy” rating in a research report on Wednesday, December 10th. Finally, Wall Street Zen cut shares of AbbVie from a “strong-buy” rating to a “buy” rating in a research note on Saturday, January 3rd. Two analysts have rated the stock with a Strong Buy rating, thirteen have given a Buy rating and eight have given a Hold rating to the company’s stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $247.84.

AbbVie Stock Performance

Shares of NYSE ABBV opened at $223.92 on Tuesday. The stock has a market capitalization of $395.75 billion, a P/E ratio of 169.64, a PEG ratio of 0.91 and a beta of 0.36. The stock’s fifty day moving average is $225.14 and its 200 day moving average is $218.00. AbbVie has a 52 week low of $164.39 and a 52 week high of $244.81.

AbbVie (NYSE:ABBV) last announced its quarterly earnings data on Friday, October 31st. The company reported $1.86 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.77 by $0.09. AbbVie had a net margin of 4.00% and a return on equity of 3,216.47%. The firm had revenue of $15.78 billion for the quarter, compared to the consensus estimate of $15.58 billion. During the same period in the prior year, the company posted $3.00 earnings per share. The business’s revenue for the quarter was up 9.1% on a year-over-year basis. AbbVie has set its Q4 2025 guidance at 3.320-3.360 EPS. Equities research analysts forecast that AbbVie will post 12.31 earnings per share for the current year.

AbbVie Increases Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, February 17th. Stockholders of record on Friday, January 16th will be paid a $1.73 dividend. The ex-dividend date of this dividend is Friday, January 16th. This represents a $6.92 dividend on an annualized basis and a dividend yield of 3.1%. This is a positive change from AbbVie’s previous quarterly dividend of $1.64. AbbVie’s dividend payout ratio (DPR) is presently 524.24%.

Institutional Inflows and Outflows

A number of institutional investors have recently modified their holdings of ABBV. Chelsea Counsel Co. acquired a new stake in AbbVie in the third quarter valued at approximately $26,000. Westend Capital Management LLC bought a new stake in AbbVie during the fourth quarter worth $29,000. Texas Capital Bancshares Inc TX bought a new stake in shares of AbbVie during the 3rd quarter worth $31,000. WestEnd Advisors LLC raised its position in AbbVie by 160.4% in the fourth quarter. WestEnd Advisors LLC now owns 138 shares of the company’s stock worth $32,000 after acquiring an additional 85 shares during the period. Finally, Evolution Wealth Management Inc. purchased a new stake in shares of AbbVie during the 2nd quarter worth approximately $26,000. Institutional investors and hedge funds own 70.23% of the company’s stock.

AbbVie News Summary

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: AbbVie struck billion‑dollar licensing deals with Novartis for oncology and Alzheimer’s programs, which expand near‑ and long‑term revenue optionality and signal external validation of AbbVie’s R&D. AbbVie and Novartis Announce Billion Dollar Licensing Deals for Oncology and Alzheimer’s Treatments
• Positive Sentiment: Berenberg raised its price target (to $275) and remains bullish on Skyrizi and Rinvoq momentum, a supportive analyst view that can boost investor sentiment. Berenberg Grows More Confident in AbbVie on Skyrizi and Rinvoq Momentum
• Positive Sentiment: AbbVie completed a Phase 1 study for an on‑body injector delivering risankizumab, which could improve dosing convenience and broaden uptake for indications served by Skyrizi. This is a pipeline/utility win. AbbVie Advances Risankizumab Delivery With On‑Body Injector Study Completion
• Positive Sentiment: Small institutional buying reported (Belpointe Asset Management increased its stake), a modest signal of shareholder confidence. Belpointe Asset Management LLC Increases Stake in AbbVie Inc. $ABBV
• Neutral Sentiment: Options and retail interest are elevated (coverage from Zacks on options flow and trending status); this can increase volatility but isn’t a fundamental catalyst by itself. Is the Options Market Predicting a Spike in AbbVie Stock?
• Neutral Sentiment: Corporate social impact news (AbbVie Foundation accelerator) and dividend‑king listings support the long‑term income story but are not immediate earnings drivers. The AbbVie Foundation Is Now Accepting Applications to Participate in the 2026 AbbVie Foundation Health Equity Accelerator
• Negative Sentiment: The U.S. Medicare Drug Price Negotiation Program named several AbbVie drugs for its next negotiation cycle, including Part B products — a direct pricing risk that could pressure future revenues if negotiated prices are reduced. US Medicare names Eli Lilly, Pfizer and AbbVie drugs for next Medicare price talks
• Negative Sentiment: A competitor (Corcept) reported robust Phase III efficacy for an ovarian cancer drug, which could threaten market share in oncology areas where AbbVie competes. Corcept’s Ovarian Cancer Drug Hits ‘Robust’ Efficacy in Phase III, Setting Up Challenge to Merck, AbbVie
• Negative Sentiment: Citigroup trimmed its price target to $230 and assigned a neutral rating, a modest analyst headwind that may cap upside near‑term. Citigroup Lowers Price Target on AbbVie

About AbbVie

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.